mRNA-LNP Based Immune Cell Engineering
 |
|
ProMab’s mRNA–LNP Toolbox enables high-efficiency CAR expression directly in immune cells, with no need for cloning, electroporation, or BSL-2 handling. This virus-free, non-integrative method ensures fast, safe, and effective delivery of genetic payloads.
|
||
Traditional viral systems are reaching their limits, constrained by biosafety restrictions, slow production cycles, and inflexible workflows. The mRNA–LNP Toolbox removes these barriers, supporting transient expression of CARs, bispecific antibodies, cytokines, and immune checkpoint regulators in T and NK cells, without relying on viral vectors or complex procedures.
Achieving transfection efficiencies of 78% to 99% while preserving genomic integrity, it offers precise, controllable expression tailored to experimental needs. Validated in peer-reviewed models of both hematologic and solid tumors, this approach enables rapid prototyping, functional screening, and in vivo studies, all within standard lab environments.
Why mRNA–LNP Is Such a Game Changer?
| Limitation / Inconvenient | Traditional Viral Vectors | mRNA–LNP |
|---|---|---|
| Cloning required | Yes | No |
| Requires BSL-2 | Yes | No |
| Genomic integration risk | Yes | No |
| Licensing / IP restrictions | Often restrictive | Publication-ready |
mRNA Tools for Next-Gen Immunotherapy, Gene Editing & Cell Engineering
| mRNA Category | Application | Key Examples |
|---|---|---|
| CAR mRNAs | Engineering CAR-T/NK cells | CD19, BCMA, HER2 – virus-free CAR constructs via mRNA-LNP |
| Bispecific Ab mRNAs | Redirecting T cells to tumors | EpCAM–CD3, HER2–CD3 – mRNA-encoded T cell engagers |
| Checkpoint scFv-Fc / mAbs | Blocking immune inhibition | PD-1 scFv-Fc, PD-L1 scFv-Fc; full IgGs like Nivolumab (anti-PD-1), Atezolizumab (anti-PD-L1) |
| Gene Editing / Antigen delivery | CRISPR or vaccine studies | Cas9-HA, COVID-19 Spike |
| Immune Modulators | Activating or suppressing immune responses | IL-4, IL-21, GM-CSF, PD-1, PD-L1 – natural regulators |
| Stem Cell Factors | Reprogramming or iPSC induction | Oct-4, SOX2 – pluripotency & lineage conversion |
| Fluorescent Reporters & mCherry mRNA-LNP | Tracking expression visually | eGFP, mCherry, Luciferase – for monitoring transfection |
| Empty LNPs | Negative control | LNPs without mRNA – for background signal validation |
mRNA-LNP Applications Across Immune Cell Types
Infographic of lipid nanoparticle LNP applications for T-cells NK cells macrophages
Application of mRNA-LNP reagents across lymphoid, myeloid, and stem-cell–derived immune systems:
- Primary T cells
- NK cells
- Macrophages
- Dendritic cells
- iPSCs and stem-cell–derived immune cells
What Sets ProMab’s mRNA Tools Apart
- 78–99% transfection efficiency in primary T, NK, iPSC, and dendritic cells
- No cloning. No viral packaging. Fast, streamlined workflows
-
100+ CAR constructs available (DNA, mRNA, LNP, or engineered cells)
-
Integrated functional assays, including real-time killing, binding, and cytokine analysis
- Clinically validated technology, supported by 40+ patents and 4 clinical-stage programs (up to Phase II)
-
References
Figure 1: Radajewska A, Przybyszewski O, Emhemmed F, Muller CD, Barg E, Moreira H. “Three-dimensional in vitro culture systems in anticancer drug discovery targeted on cancer stem cells." Am J Cancer Res. 2021 Oct 15;11(10):4931-4946. PMID: 34765301; PMCID: PMC8569359.
Figure 2: Courtesy of Apricell Biotechnology Inc..
Figure 3 : Courtesy of Kugelmeiers.
Figure 4: Courtesy of 4Dcell.
Custom Project? Let’s Talk.
Tebubio is the exclusive European scientific interface of ProMab, providing direct access to expertise and tailored CRO support.